{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emtricitabine+placebo&page=2",
    "query": {
      "intervention": "Emtricitabine placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emtricitabine+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emtricitabine+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T03:08:12.949Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00244712",
      "title": "Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "emtricitabine/tenofovir",
          "type": "DRUG"
        },
        {
          "name": "abacavir/lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 688,
      "start_date": "2005-07",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2010-06-08",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 72,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244712"
    },
    {
      "nct_id": "NCT06630286",
      "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "ISL/LEN",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "PTM B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "PTM ISL/LEN",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 609,
      "start_date": "2024-10-09",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630286"
    },
    {
      "nct_id": "NCT07795307",
      "title": "Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Emtricitabine and tenofovir disoproxil fumarate combination",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-12",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07795307"
    },
    {
      "nct_id": "NCT01263015",
      "title": "A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus I"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Atripla",
          "type": "DRUG"
        },
        {
          "name": "Abacavir/Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Abacavir/Lamivudine Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir placebo",
          "type": "DRUG"
        },
        {
          "name": "Atripla placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 844,
      "start_date": "2011-02-01",
      "completion_date": "2015-12-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-04",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 55,
      "location_summary": "Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01263015"
    },
    {
      "nct_id": "NCT02397694",
      "title": "Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "BIC",
          "type": "DRUG"
        },
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "BIC Placebo",
          "type": "DRUG"
        },
        {
          "name": "DTG Placebo",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2015-03-23",
      "completion_date": "2019-02-27",
      "has_results": true,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397694"
    },
    {
      "nct_id": "NCT00117676",
      "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "ADV",
          "type": "DRUG"
        },
        {
          "name": "TDF placebo",
          "type": "DRUG"
        },
        {
          "name": "ADV placebo",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 382,
      "start_date": "2005-02",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Pasadena, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00117676"
    },
    {
      "nct_id": "NCT00002335",
      "title": "The Safety and Effectiveness of 524W91",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glaxo Wellcome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002335"
    },
    {
      "nct_id": "NCT00708162",
      "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Elvitegravir",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "EVG placebo",
          "type": "DRUG"
        },
        {
          "name": "RAL placebo",
          "type": "DRUG"
        },
        {
          "name": "Background regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 724,
      "start_date": "2008-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-05-30",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 94,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708162"
    },
    {
      "nct_id": "NCT01797445",
      "title": "Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TDF",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 872,
      "start_date": "2013-03-12",
      "completion_date": "2018-10-03",
      "has_results": true,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 79,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01797445"
    },
    {
      "nct_id": "NCT03547908",
      "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1/HBV Co-Infection"
      ],
      "interventions": [
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match DTG",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match F/TDF",
          "type": "DRUG"
        },
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 244,
      "start_date": "2018-05-30",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-10-04T03:08:12.949Z",
      "location_count": 4,
      "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Berkley",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547908"
    }
  ]
}